Biotech & Pharma · Week of Nov 9, 2026
Eli Lilly and Company, Rezolute report trial data: the week in biotech
Viking Therapeutics, Werewolf Therapeutics, Protalix, Trevi, TuHURA and Edesa also reported, with conference data and Q3 updates setting the week's pace.
Medical meetings drove much of the week's news. Eli Lilly and Company and Viking Therapeutics both brought obesity data to ObesityWeek 2026 in Washington, D.C., running November 14 to 17. Lilly's data covered Zepbound, Foundayo, EloraTZP, eloralintide and retatrutide, while Viking showed an exploratory analysis of its Phase 2 VENTURE trial of VK2735. Werewolf Therapeutics presented WTX-124 and WTX-330 data at SITC 2026. Protalix BioTherapeutics presented PRX-115 gout-related data at ACR Convergence 2026.
Third quarter reports from Trevi Therapeutics and TuHURA Biosciences showed different financial positions. Trevi reported $299.4 million in cash and marketable securities, which it expects to fund operations into 2030. TuHURA reported $1.9 million in cash and cash equivalents. In other news, Rezolute said its Phase 3 upLIFT study in tumor hyperinsulinism met its primary endpoint. Edesa Biotech licensed Japanese rights to paridiprubart to KYORIN Pharmaceutical for a $12 million upfront payment.

Eli Lilly and Company
Lilly to present new data across Zepbound, Foundayo, EloraTZP and retatrutide at ObesityWeek 2026, moving obesity care beyond the scale
Eli Lilly and Company said it will present data on Zepbound, Foundayo, EloraTZP, eloralintide and retatrutide at ObesityWeek 2026, including Phase 2 results in which EloraTZP produced weight loss of up to an average of 54.1 lbs (23.3%) at 48 weeks in adults with type 2 diabetes. Lilly also reported that in TRIUMPH-1, retatrutide reduced the apnea-hypopnea index by up to an average of 60.6% at 80 weeks, extending its obesity data into sleep apnea and knee osteoarthritis pain.
Trevi Therapeutics, Inc.
Trevi Therapeutics Reports Third Quarter 2026 Financial Results and Provides Business Updates
Trevi Therapeutics reported a third quarter 2026 net loss of $21.5 million and $299.4 million in cash, cash equivalents and marketable securities, which it expects to provide runway into 2030. The company expects OCEAN-2 Phase 3 topline results in the second half of 2027 and plans a roughly 120-patient Phase 2 trial in non-IPF ILD-related chronic cough in the first quarter of 2027, subject to FDA protocol review.

Protalix BioTherapeutics, Inc.
Higher Single PRX-115 Doses Kept Plasma Uric Acid Levels Below Therapeutic Target for Longer Durations
Protalix BioTherapeutics reported higher-dose Phase 1 data for PRX-115 at ACR Convergence 2026, saying mean plasma uric acid stayed below the 6.0 mg/dL target for up to 12 weeks after a single 36 mg infusion. The company said previously reported safety data included one anaphylactic reaction that resolved, and it expects top-line Phase 2 RELEASE results in the second half of 2027.

TuHURA Biosciences, Inc.
TuHURA Biosciences Reports Third Quarter 2026 Financial Results and Provides a Corporate Update
TuHURA Biosciences reported $1.9 million in cash and cash equivalents at September 30, 2026, and said it has drawn $9.2 million in gross proceeds on the Parkview credit facility. The company received FDA IND clearance for a Phase 1b study of TBS-2025 in relapsed/refractory mutNPM1 AML after Menin inhibitor therapy.
Werewolf Therapeutics, Inc.
Werewolf Therapeutics’ Clinical Data for WTX-124 and WTX-330 Presented at the Society for Immunotherapy of Cancer’s (SITC) 2026 Annual Meeting
Werewolf Therapeutics presented data at SITC 2026 showing a 37.5% response rate for WTX-124 plus pembrolizumab in NSCLC patients with prior chemoimmunotherapy, from a 155-patient Phase 1/1b trial. The company says it has aligned with the FDA on a recommended phase two dose of 18 mg IV Q2W and reported no evidence of vascular leak syndrome with either molecule.

Viking Therapeutics, Inc
Viking Therapeutics Highlights Clinical Data from VK2735 Obesity Program at ObesityWeek® 2026
Viking Therapeutics said an exploratory VENTURE analysis showed 74% of participants on weekly subcutaneous VK2735 improved by at least one BMI category after 13 weeks, compared with 15% on placebo. A second poster described baseline characteristics of the ongoing Phase 3 VANQUISH-2 study in adults with overweight or obesity and type 2 diabetes.
Edesa Biotech, Inc.
Edesa Biotech Announces Agreement with KYORIN Pharmaceutical to Develop and Commercialize Paridiprubart in Japan
Edesa Biotech granted KYORIN Pharmaceutical an exclusive license to develop and commercialize paridiprubart for ARDS in Japan, for a $12 million upfront payment and milestones of up to approximately $134 million, plus tiered double-digit royalties. Edesa retains rights outside Japan and cites a Phase 3 study showing adjusted 28-day mortality risk of 39% versus 52% for placebo.
Rezolute, Inc.
Rezolute Announces Positive Results from the Phase 3 upLIFT Study in Tumor Hyperinsulinism
Rezolute said the open-label Phase 3 upLIFT study of ersodetug in tumor hyperinsulinism met its primary efficacy endpoint, with 13 of 16 participants meeting the responder criterion, above the 9 needed for statistical significance. The company said 12 responders discontinued IV glucose entirely and expects complete results by mid-December 2026.
This roundup is written with AI assistance from the press releases listed above, using only what they state. The releases are the companies' own announcements, not News Today Lines reporting.